Abstract
Objectives:Lactobacillus reuteri Fn041 (Fn041) is a probiotic isolated from immunoglobulin A coated microbiota in the human breast milk of Gannan in China with a low incidence of hypercholesterolemia. This study aims to explore the role and mechanism of Fn041 in preventing hypercholesterolemia caused by a high-fat diet in mice.MethodsC57BL/6N mice were fed a low-fat diet or a high-fat diet and gavage with Fn041 and Lactobacillus rhamnosus GG (LGG) for 8 weeks.ResultsBoth Fn041 and LGG prevented the occurrence of hypercholesterolemia, liver and testicular fat accumulation. In addition, a high-fat diet causes intestinal dysbiosis and mucosal barrier damage, which is associated with hypercholesterolemia. Fn041 prevented the high-fat diet-induced reduction in alpha diversity of intestinal microbiota and intestinal mucosal barrier damage. Fn041 treatment significantly increased fecal total cholesterol and total bile acids.ConclusionsFn041 prevented hypercholesterolemia by enhancing cholesterol excretion and mucosal barrier function.
Highlights
Chronic exposure to a high-fat diet can lead to an accumulation of cholesterol in the blood [1]
We found that Fn041 alleviates the effect of high-fat diet-induced dyslipidemia in mice [17]; we further increased the fat supply ratio to observe whether Fn041 could prevent dyslipidemia and compared its results with those of the typical probiotic Lactobacillus rhamnosus GG (LGG) to determine whether the cholesterollowering efficacies and mechanisms of the two strains were the same
Our study demonstrated that Fn041 prevented high-fat dietinduced hypercholesterolemia, prevented intestinal barrier function damage, and improved intestinal microbiota disorders in mice
Summary
Chronic exposure to a high-fat diet can lead to an accumulation of cholesterol in the blood [1]. An elevated plasma total cholesterol (TC) level is a recognized risk factor for coronary heart disease, atherosclerosis, and strokes [2]. Successful management of cholesterol metabolism disorders can effectively prevent these diseases [3]. There is growing evidence that gut microbiota dysbiosis strongly influences the development of cholesterol metabolism [4, 5]. Statins are currently the most effective cholesterol-lowering drugs. Their long-term use can have side effects such as hepatotoxicity and muscle toxicity [6]. There is a need to develop nutritional interventions with no side effects
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
